CelLBxHealth PLC (CLBX)

Industry Diagnostics & Research

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

2.30p

Buy

2.50p

arrow-down-0.25p (-9.43%)

Prices updated at 28 Oct 2025, 16:18 GMT

Prices minimum 15 mins delay

Prices in GBX

ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

-

CEO

-

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

119

Head office

10 Nugent Road

Guildford

United Kingdom

GU2 7AF

+44 1483343434

investor@angleplc.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Brian Howlett Non-Executive Director, Senior Independent Director	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	2,769,230
Unicorn AIM VCT Series 3 ORD	2,769,230
Hargreave Hale Limited	1,871,174
Hargreave Hale AIM VCT	1,871,174
Pinnacle Associates Inc	634,348

Director dealings

Date chevron-l-regular chevron-r-regular	Action
No data

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.